Patient Experiences Initiating Continuous Subcutaneous Apomorphine Infusion (CSAI): An Interview-Based Survey of InfusON Study Participants
Objective: Obtain patient feedback on experiences initiating and using continuous subcutaneous apomorphine infusion (CSAI). Background: Previously reported data from the ongoing InfusON study demonstrated that…Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat
Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…Targeting miR-27 with Antisense Oligonucleotides for Disease Modification in Parkinson’s Disease
Objective: Achieve disease modification in idiopathic Parkinson’s Disease through miR-27 targeting using Antisense Oligonucleotides Background: There are currently no disease-modifying therapies for Parkinson’s Disease (PD).…Association between Fecal Bile Acids and Levodopa Response in Patients with Parkinson’s Disease
Objective: We sought to determine whether fecal bile acids (BAs) could affect levodopa response assessed by levodopa challenge test (LCT) in patients with Parkinson’s disease…A Preliminary Report on the Clinical Profile of People with PD at an Outpatient Clinic in Malawi
Objective: The objective of the study is to analyze the clinical and socio-demographic characteristics of people with Parkinson`s (PwP) attending the adult neurology outpatient clinic…Pharmacokinetics of Levodopa after Subcutaneous bolus delivery of foslevodopa/foscarbidopa
Objective: To characterize the pharmacokinetics (PK) of levodopa (LD) after bolus delivery of foslevodopa/foscarbidopa Background: Foslevodopa/foscarbidopa is a soluble formulation of LD/CD prodrugs delivered as…Long term evaluation of gluten-free diet in Parkinson´s disease patients
Objective: The primary aim of the project was to evaluate the effect of long-term administered gluten-free diet (GFD) on motor symptoms of Parkinson's disease (PD).…Istradefylline therapy for dystonia in Parkinson’s disease
Objective: To clarify the basal ganglia network links between PD and Dystonia in PD (Dys-PD) co-occur, and to get the conceptually novel pharmacotherapy. Background: Dys-PD is one…Preclinical Studies: Investigating Serum-Based Exosomal miRNAs in Prodromal Drug-Induced Parkinson’s Disease
Objective: This work aims to elucidate the identification of homologs of miRNAs in a pronormal stage of Parkinson`s disease. Background: Parkinson's disease (PD) is defined…Differences in Molecular and Ultrastructural profiles of astroglia and microglia in substantia nigra of two different mice strains in normal aging and experimental Parkinsonism
Objective: To examine whether the variable sensitivity of dopaminergic neurons of the substantia nigra pars compacta -SNpc- in C57BL/6J and CD-1 mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ MPTP…
- « Previous Page
- 1
- …
- 87
- 88
- 89
- 90
- 91
- …
- 181
- Next Page »